AG
PCRX icon

AIA Group’s Pacira BioSciences PCRX Stock Holding History

AIA Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-64,391
Closed -$1.98M – 295
2023
Q3 		$1.98M Buy
64,391
+11,198
+21% +$404K 0.1% 106
2023
Q2 		$2.13M Sell
53,193
-5,644
-10% -$233K 0.1% 98
2023
Q1 		$2.4M Buy
58,837
+32,702
+125% +$1.3M 0.13% 67
2022
Q4 		$1.01M Sell
26,135
-17,349
-40% -$844K 0.06% 139
2022
Q3 		$2.31M Buy
43,484
+1,452
+3% +$80.7K 0.15% 61
2022
Q2 		$2.45M Sell
42,032
-6,092
-13% -$399K 0.13% 72
2022
Q1 		$3.67M Sell
48,124
-74,642
-61% -$4.98M 0.16% 54
2021
Q4 		$7.39M Buy
122,766
+46,385
+61% +$2.56M 0.35% 43
2021
Q3 		$4.28M Buy
76,381
+12,983
+20% +$748K 0.24% 63
2021
Q2 		$3.56M Buy
63,398
+2,553
+4% +$162K 0.24% 62
2021
Q1 		$4.26M Buy
60,845
+21,661
+55% +$1.55M 0.62% 48
2020
Q4 		$2.8M Buy
+39,184
New +$2.29M 0.32% 47

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

AIA Group's PCRX Position: Q4 2023 in Review

AIA Group sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 64,391 shares — an estimated $1.98M sold.

AIA Group first reported a position in PCRX in Q4 2020 and held it in 12 quarters. The position peaked at $7.39M in Q4 2021. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

  • AIA Group reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
  • AIA Group sold 64,391 Pacira BioSciences shares in Q4 2023, an estimated $1.98M.
  • AIA Group first reported a position in Pacira BioSciences in Q4 2020 and held it in 12 quarters.
  • AIA Group's Pacira BioSciences position peaked at $7.39M in Q4 2021.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on AIA Group's 13F filing for Q4 2023, filed 31 Jan 2024.